Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Zengyu Feng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108820241. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2020: 1 paper · 2021: 5 papers · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 16

  1. LINC01137 facilitates pancreatic cancer stemness, chemoresistance and proliferation via the miR-7155-5p/KLF12/PI3K-Akt axis. Co-author DOI 10.1016/j.ijbiomac.2026.150088↗
  2. SEC14L2 contributes to tumor progression by enhancing USP5-driven RBM3 deubiquitination in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-026-03968-6↗
  3. Unraveling the Role of MDK-SDC4 Interaction in Pancreatic Cancer-Associated New-Onset Diabetes by Single-Cell Transcriptomic Analysis. Co-author DOI 10.1002/advs.202409987↗
  4. Sorcin can trigger pancreatic cancer-associated new-onset diabetes through the secretion of inflammatory cytokines such as serpin E1 and CCL5. Co-author DOI 10.1038/s12276-024-01346-4↗
  5. Author Correction: Sorcin can trigger pancreatic cancer-associated new-onset diabetes through the secretion of inflammatory cytokines such as serpin E1 and CCL… Co-author DOI 10.1038/s12276-024-01363-3↗
  6. Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Co-author DOI 10.1186/s13045-023-01506-5↗
  7. LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2411868/v1↗
  8. The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Co-author DOI 10.1186/s13045-022-01338-9↗
  9. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-1516835/v1↗
  10. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis First author DOI 10.21203/rs.3.rs-2065916/v1↗
  11. A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implicati… Co-author DOI 10.3389/fcell.2021.619549↗
  12. An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fcell.2021.665161↗
  13. A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmolb.2021.650264↗
  14. Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmolb.2021.659168↗
  15. Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmolb.2021.676291↗
  16. Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02527-1↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kexian Li · 11 shared papers, 2020–2023 · strength 1.62
  2. Chenghong Peng · 10 shared papers, 2021–2023 · strength 1.50
  3. Yulian Wu · 8 shared papers, 2021–2025 · strength 1.40
  4. Kai Qin · 7 shared papers, 2022–2026 · strength 1.24
  5. Lingxi Jiang · 5 shared papers, 2020–2023 · strength 0.68
  6. Yizhi Cao · 4 shared papers, 2022–2026 · strength 0.65
  7. Hongxia Xu · 3 shared papers, 2024–2026 · strength 0.63
  8. Xiawei Li · 3 shared papers, 2024–2025 · strength 0.61
  9. Jiali Gong · 3 shared papers, 2024–2025 · strength 0.61
  10. Hao Chen · 3 shared papers, 2022–2023 · strength 0.45
  11. Jiewei Lin · 3 shared papers, 2022–2023 · strength 0.41
  12. Lijie Han · 3 shared papers, 2022–2023 · strength 0.41
  13. Yongsheng Jiang · 3 shared papers, 2022–2023 · strength 0.41
  14. Hao Chen · 3 shared papers, 2020–2022 · strength 0.38
  15. Yongji Sun · 2 shared papers, 2024 · strength 0.34
  16. Qiaojun He · 2 shared papers, 2024 · strength 0.34
  17. Yizhao Zhou · 2 shared papers, 2024 · strength 0.34
  18. Chenghong Peng · 1 shared paper, 2026 · strength 0.29
  19. Jiancheng Wang · 2 shared papers, 2022–2023 · strength 0.28
  20. Jiaxin Luo · 2 shared papers, 2022–2023 · strength 0.28
  21. Kexian Li · 1 shared paper, 2026 · strength 0.24
  22. Chenghong Peng · 1 shared paper, 2026 · strength 0.24
  23. Zhichong Wu · 1 shared paper, 2026 · strength 0.24
  24. Xiaxing Deng · 1 shared paper, 2026 · strength 0.24
  25. Lijie Han · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.